.png)
.png)
Exploristics announces global launch of the Spring 2021 release of its clinical trial design platform, KerusCloud.
Exploristics announces global launch of the Spring 2021 software release of its clinical trial design platform, KerusCloud
05 MAY 21
Belfast, UK - 5 May 2021. Exploristics is pleased to announce the global launch of the Spring 2021 release of its ground-breaking clinical trial design platform, KerusCloud.
Accelerating development to meet clinical need has never been more urgent in the pandemic era. For over ten years now, Exploristics has been providing specialist statistical software and biostatistics consultancy services to support the design, analysis and reporting of clinical trials and real-world studies. Our uniquely targeted statistical approach has been shown to fast-track clinical development by increasing study success while reducing risks and costs.
With many of our development solutions built around our ground-breaking clinical trial design software, KerusCloud, Exploristics are pleased to announce the global launch of its Spring 2021 release. This transformative cloud-based SaaS simulation platform allows clinical development teams to explore multiple study design and analysis options in silico, in minutes, for earlier data-driven design decisions. With KerusCloud, clinical studies can be extensively optimised statistically from the outset, maximising their chances of success.
The Spring 2021 release of the KerusCloud software platform includes a range of innovative features tailored to provide further quantitative insights to support evidence-based decision-making during clinical protocol development. To support its launch, Exploristics will be running a series of free live introductory webinars during May to July 2021, hosted by Exploristics’ CEO, Aiden Flynn.
Exploristics CEO, Aiden Flynn commented: “We are delighted to be launching the latest version of this innovative study simulation software. There is an urgent need to take a more holistic approach to study design and planning, one that moves beyond the siloed approach of the past. That’s why Exploristics has built a new platform and ecosystem called KerusCloud, that places statistics and data sciences at the heart of informed decision-making and to reduce the risks and costs of clinical development.”
About Exploristics
Exploristics is a world-leading provider of biosimulation software and biostatistics services for designing, analysing and reporting clinical trials and real-world studies. Our unique approach transforms clinical development through our study design platform, KerusCloud, and specialist consultancy services.
Founded in 2009, Exploristics has been delivering innovative analytics solutions to the life sciences sector for over ten years. With in-depth experience of the challenges of life science research, we offer innovation and a fresh perspective to biostatistics support for clinical development.
With extensive experience supporting the development of medicines and medical technologies, we have keen insight into the best statistical approaches for understanding and exploiting clinical data. We offer a creative, customer-focused culture supported by standards and processes that ensure quality whilst enabling innovation. This combination makes us the ideal partner for the provision of knowledge-based, flexible and innovative study design and data analysis capabilities for life sciences.
Emerging opportunities to integrate real-world data sources throughout the development process means that statistical considerations should be placed at the heart of every clinical study. We add value to development programmes by getting involved at the earliest planning stages to ensure that projects are driven by evidence-based decision-making from inception to completion. We believe that clinical studies are more insightful, successful and efficient at delivering new medical interventions to those in need when designed with sound statistics at their core.
FOR MORE INFORMATION
Exploristics
Aiden Flynn, CEO & Founder
[email protected]
05 MAY 21
Belfast, UK - 5 May 2021. Exploristics is pleased to announce the global launch of the Spring 2021 release of its ground-breaking clinical trial design platform, KerusCloud.
Accelerating development to meet clinical need has never been more urgent in the pandemic era. For over ten years now, Exploristics has been providing specialist statistical software and biostatistics consultancy services to support the design, analysis and reporting of clinical trials and real-world studies. Our uniquely targeted statistical approach has been shown to fast-track clinical development by increasing study success while reducing risks and costs.
With many of our development solutions built around our ground-breaking clinical trial design software, KerusCloud, Exploristics are pleased to announce the global launch of its Spring 2021 release. This transformative cloud-based SaaS simulation platform allows clinical development teams to explore multiple study design and analysis options in silico, in minutes, for earlier data-driven design decisions. With KerusCloud, clinical studies can be extensively optimised statistically from the outset, maximising their chances of success.
The Spring 2021 release of the KerusCloud software platform includes a range of innovative features tailored to provide further quantitative insights to support evidence-based decision-making during clinical protocol development. To support its launch, Exploristics will be running a series of free live introductory webinars during May to July 2021, hosted by Exploristics’ CEO, Aiden Flynn.
Exploristics CEO, Aiden Flynn commented: “We are delighted to be launching the latest version of this innovative study simulation software. There is an urgent need to take a more holistic approach to study design and planning, one that moves beyond the siloed approach of the past. That’s why Exploristics has built a new platform and ecosystem called KerusCloud, that places statistics and data sciences at the heart of informed decision-making and to reduce the risks and costs of clinical development.”
About Exploristics
Exploristics is a world-leading provider of biosimulation software and biostatistics services for designing, analysing and reporting clinical trials and real-world studies. Our unique approach transforms clinical development through our study design platform, KerusCloud, and specialist consultancy services.
Founded in 2009, Exploristics has been delivering innovative analytics solutions to the life sciences sector for over ten years. With in-depth experience of the challenges of life science research, we offer innovation and a fresh perspective to biostatistics support for clinical development.
With extensive experience supporting the development of medicines and medical technologies, we have keen insight into the best statistical approaches for understanding and exploiting clinical data. We offer a creative, customer-focused culture supported by standards and processes that ensure quality whilst enabling innovation. This combination makes us the ideal partner for the provision of knowledge-based, flexible and innovative study design and data analysis capabilities for life sciences.
Emerging opportunities to integrate real-world data sources throughout the development process means that statistical considerations should be placed at the heart of every clinical study. We add value to development programmes by getting involved at the earliest planning stages to ensure that projects are driven by evidence-based decision-making from inception to completion. We believe that clinical studies are more insightful, successful and efficient at delivering new medical interventions to those in need when designed with sound statistics at their core.
FOR MORE INFORMATION
Exploristics
Aiden Flynn, CEO & Founder
[email protected]